Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Trillium Meds vs Clume Health

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Better valueGrade C · #65

Trillium Meds

Cost-first shoppers who want all-50-state compounded GLP-1 with a real month-to-month option and a cheaper 3-month prepay path.

Visit Trillium Meds
VS
Grade C · #66

Clume Health

Readers who want the dispensing pharmacies named up front and do not need the price broken out by molecule.

Visit Clume Health

The verdict

Too close to callGrade C vs C

Trillium Meds and Clume Health tie on the Cost-Efficiency Index at 73/100, so neither wins outright on the numbers. For most shoppers we'd start with Trillium Meds (ranked #65, a hair above #66) — Cost-first shoppers who want all-50-state compounded GLP-1 with a real month-to-month option and a cheaper 3-month prepay path. But Clume Health is a genuine coin-flip alternative here.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Trillium Meds.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

66
51

Price Transparency

94
92

Nationwide Access

86
86

Formulation Options

66
77

Clinical Oversight

89
68

Contract Flexibility

20
67

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecTrillium MedsClume Health
Cost-Efficiency Index73/10073/100
Semaglutide / mo$159/mo (all doses, compounded)$259/month month-to-month (one Signature price covers semaglutide or tirzepatide, oral or injectable; $186/mo needs a 52-week plan)
Tirzepatide / mo$249/mo (all doses, compounded)$259/month month-to-month (the same Signature price; $186/mo needs a 52-week plan)
Semaglutide / yr (modeled)$1,908$3,108
Tirzepatide / yr (modeled)$2,988$3,108
CoverageAll 50 statesAll 50 states
Oral / sublingualNoYes
Brand-name accessCompounded onlyCompounded only
Rank here#65#66

Trillium Meds

73/100

Where the value is

  • Discloses both a real month-to-month rate ($159/$249) and the 3-month prepay rate, rather than only advertising the lower prepay number
  • LegitScript certified, all 50 states plus Puerto Rico, with a real street address published
  • Syringes and alcohol wipes included; Klarna and Affirm financing available

The tradeoffs

  • The lowest advertised rate ($119/mo semaglutide, ~$200/mo tirzepatide) requires a $357 or $599 upfront 3-month payment, not a standing monthly charge
  • Partner pharmacy names are referenced in the FAQ structure but were not visible in the page text pulled this session — re-verify before citing a specific pharmacy
Visit Trillium Meds

Full Trillium Meds review →

Clume Health

73/100

Where the value is

  • Names all four dispensing pharmacies with street addresses, phone numbers and websites, so a buyer can look up who actually compounds the prescription
  • The price is published before the intake and covers the consultation, ongoing oversight, the medication and delivery
  • One figure covers semaglutide, tirzepatide, oral and injectable, so switching molecule or route does not change the bill

The tradeoffs

  • Both headline prices on the homepage match nothing on sale: "*$199/month" against real floors of $259 and $219, and "*$159/month" against $216 — and neither asterisk resolves to a footnote
  • The cheaper monthly figures are commitments rather than rates: $186 a month requires a 52-week plan and $200 a month a 12-week one
Visit Clume Health

Full Clume Health review →

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons